As expected, gefitinib efficiently suppressed EGFR kinase activity as seen in the decreased phosphorylated level of activation site, Tyr1197 in EGFR, accompanying by the lower EGFR expression in a time-dependent manner in fours NSCLC models (supplemental Fig. S3A). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.